Figure 1
From: Targeting the NF-κB pathway enhances responsiveness of mammary tumors to JAK inhibitors
Macrophages mediate resistance of the tumor cells to JAK inhibitor ruxolitinib. Cell survival was measured by Crystal Violet Assay and absorbance was measured at 590 nm for HC11/R1 (a) and 4T1 (b) cells co-cultured with macrophages. HC11/R1 (c) and 4T1 cells (d) were treated with conditioned media from macrophages treated with ruxolitinib only, without tumor conditioned media. Tumor cell survival was measured using crystal violet assay *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 3 biological replicates.
